Mycophenolate mofetil.
Mycophenolate mofetil is the morpholinoethylester prodrug of mycophenolic acid, an agent that inhibits the proliferation of B and T lymphocytes through noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, a key enzyme in the de novo synthetic pathway of guanine nucleotides. Currently, mycophenolate mofetil is approved for the prevention of acute renal allograft rejection when given in combination with cyclosporine and steroids. Several studies also demonstrated that the agent is effective in the treatment of refractory rejection in renal, heart, and liver transplant recipients, and may have efficacy in the treatment of chronic rejection as well.
Sievers
T M
TM
Department of Surgery, Center for Liver Diseases and Transplantation, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Rossi
S J
SJ
Ghobrial
R M
RM
Arriola
E
E
Nishimura
P
P
Kawano
M
M
Holt
C D
CD
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006084:Graft Rejection / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D007408:Intestinal Absorption; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid